Viatris Inc. has announced its financial results for the second quarter of 2024, highlighting approximately 2% operational growth, reaching net revenues of USD 3.8 billion. Both the generics and brands segments experienced a rise of about 2% each during the quarter. The company also reported new product revenues amounting to USD 210 million, including sales of Breyna in the U.S., which is Pfizer’s generic version of AstraZeneca’s asthma therapy Symbicort (budesonide and formoterol fumarate dihydrate).
With a global footprint spanning over 160 markets, Viatris has noted a net sales growth of about 5% in Greater China compared to the previous year. This growth has been attributed to robust demand across various channels, including e-commerce, retail, and private hospitals, as stated by company executives during the earnings call.
According to Viatris’ SEC filing, total revenues in the Greater China region for Q2’24 stood at USD 539 million, marking an increase from USD 532.1 million in Q2’23. The majority of these sales were concentrated on Established Brands, with a minor contribution of USD 3.3 million from Pfizer’s Generics portfolio. For the first half of 2024, the China market contributed USD 1,082.9 million in sales, slightly down from the USD 1,096.7 million reported in the first half of 2023.- Flcube.com
